Tags

Type your tag names separated by a space and hit enter

Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience.
Liver Int. 2013 May; 33(5):722-6.LI

Abstract

BACKGROUND

The role of ribavirin for treatment of severe acute or chronic hepatitis E virus (HEV) infection is not well defined.

AIMS

To investigate the applicability and efficacy of ribavirin therapy in acute and chronic HEV infections within a large single-centre cohort.

MATERIALS & METHODS

Clinical courses of forty-four German HEV-infected individuals were analysed.

RESULTS

In a prospective case series, we observed spontaneous recovery from acute symptomatic HEV-infection in 10/11 immunocompetent individuals. Ribavirin therapy was initiated in one patient with severe acute HEV-genotype-1e infection who rapidly improved liver function and cleared HEV. Of 15 organ transplant recipients with prolonged HEV viraemia, reduction in immunosuppression led to HEV-clearance in three patients, while ribavirin therapy was initiated in 11 subjects. A rapid response with undetectable HEV-RNA occurred in nine subjects. One patient died after experiencing a virological breakthrough associated with ribavirin dose reduction because of severe anaemia.

DISCUSSION

Ribavirin is a safe treatment option for HEV infections. However, the optimal dose of ribavirin for the treatment of chronic hepatitis E remains to be determined as treatment failure may occur.

Authors+Show Affiliations

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23489973

Citation

Pischke, Sven, et al. "Ribavirin Treatment of Acute and Chronic Hepatitis E: a Single-centre Experience." Liver International : Official Journal of the International Association for the Study of the Liver, vol. 33, no. 5, 2013, pp. 722-6.
Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33(5):722-6.
Pischke, S., Hardtke, S., Bode, U., Birkner, S., Chatzikyrkou, C., Kauffmann, W., Bara, C. L., Gottlieb, J., Wenzel, J., Manns, M. P., & Wedemeyer, H. (2013). Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver International : Official Journal of the International Association for the Study of the Liver, 33(5), 722-6. https://doi.org/10.1111/liv.12114
Pischke S, et al. Ribavirin Treatment of Acute and Chronic Hepatitis E: a Single-centre Experience. Liver Int. 2013;33(5):722-6. PubMed PMID: 23489973.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. AU - Pischke,Sven, AU - Hardtke,Svenja, AU - Bode,Ulrike, AU - Birkner,Stephan, AU - Chatzikyrkou,Christos, AU - Kauffmann,Wolfgang, AU - Bara,Christoph L, AU - Gottlieb,Jens, AU - Wenzel,Juergen, AU - Manns,Michael P, AU - Wedemeyer,Heiner, Y1 - 2013/03/13/ PY - 2012/09/20/received PY - 2012/12/20/accepted PY - 2013/3/16/entrez PY - 2013/3/16/pubmed PY - 2013/9/24/medline SP - 722 EP - 6 JF - Liver international : official journal of the International Association for the Study of the Liver JO - Liver Int VL - 33 IS - 5 N2 - BACKGROUND: The role of ribavirin for treatment of severe acute or chronic hepatitis E virus (HEV) infection is not well defined. AIMS: To investigate the applicability and efficacy of ribavirin therapy in acute and chronic HEV infections within a large single-centre cohort. MATERIALS & METHODS: Clinical courses of forty-four German HEV-infected individuals were analysed. RESULTS: In a prospective case series, we observed spontaneous recovery from acute symptomatic HEV-infection in 10/11 immunocompetent individuals. Ribavirin therapy was initiated in one patient with severe acute HEV-genotype-1e infection who rapidly improved liver function and cleared HEV. Of 15 organ transplant recipients with prolonged HEV viraemia, reduction in immunosuppression led to HEV-clearance in three patients, while ribavirin therapy was initiated in 11 subjects. A rapid response with undetectable HEV-RNA occurred in nine subjects. One patient died after experiencing a virological breakthrough associated with ribavirin dose reduction because of severe anaemia. DISCUSSION: Ribavirin is a safe treatment option for HEV infections. However, the optimal dose of ribavirin for the treatment of chronic hepatitis E remains to be determined as treatment failure may occur. SN - 1478-3231 UR - https://www.unboundmedicine.com/medline/citation/23489973/Ribavirin_treatment_of_acute_and_chronic_hepatitis_E:_a_single_centre_experience_ L2 - https://doi.org/10.1111/liv.12114 DB - PRIME DP - Unbound Medicine ER -